Optimizing Treatment Strategies in Myeloma Cast Nephropathy: Rationale for a Randomized Prospective Trial

Advances in Chronic Kidney Disease

Volumn 19, Issue 5, 2012, Pages 333-341

  Bridoux, Frank ^a   Fermand, Jean Paul ^a  

^a Section of Radiology   (France)

Author keywords

Chemotherapy; Epidemiology; Free light chains; High cut off dialysis; Multiple myeloma; Myeloma cast nephropathy

Indexed keywords

ANTIBIOTIC AGENT; BENDAMUSTINE; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; COLCHICINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; TAMM HORSFALL GLYCOPROTEIN; THALIDOMIDE; VINCRISTINE;

CRYOGLOBULINEMIA; DIALYSIS MEMBRANE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; EMERGENCY TREATMENT; FANCONI RENOTUBULAR SYNDROME; FLUID THERAPY; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; IMMUNOGLOBULIN DEPOSITION; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY INTERSTITIUM; KIDNEY TUBULE DISORDER; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CAST NEPHROPATHY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SURVIVAL TIME; THROMBOCYTOPENIA;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GLOMERULONEPHRITIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY TUBULES, PROXIMAL; MULTIPLE MYELOMA; PLASMA EXCHANGE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS;

EID: 84865408818     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.07.003     Document Type: Review

References (61)

1. Rayner H.C., Haynes A.P., Thompson J.R., Russell N., Fletcher J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med 1991, 79:517-525.
2. Rota S., Mougenot B., Baudouin B., et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987, 66:126-137.
3. Pirani C.L., Silva F., D'Agati V., Chander P., Striker L.M. Renal lesions in plasma cell dyscrasias: ultrastructural observations. Am J Kidney Dis 1987, 10:208-221.
4. Sakhuja V., Jha V., Varma S., et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000, 22:465-477.
5. Preud'homme J.L., Aucouturier P., Touchard G., et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994, 46:965-972.
6. Touchard G. Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits. Monoclonal Gammopathies and the Kidney 2003, 95-117. Kluwer Academic Publishers, Dordrecht. G. Touchard, P. Aucouturier, O. Hermine, P. Ronco (Eds.).
7. Hutchison C.A., Batuman V., Behrens J., et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2011, 8:43-51.
8. Li M., Balamuthusamy S., Simon E.E., Batuman V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am J Physiol Renal Physiol 2008, 295:F82-F90.
9. Pozzi C., Pasquali S., Domini U., et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Clin Nephrol 1987, 28:1-9.
10. Messiaen T., Deret S., Mougenot B., et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 2000, 79:135-154.
11. Gu X., Herrera G.A. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol lab Med 2006, 130:165-169.
12. Bridoux F., Hugue V., Coldefy O., et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunological features. Kidney Int 2002, 62:1764-1775.
13. Bridoux F., Sirac C., Jaccard A., et al. Renal disease in cryoglobulinemic vasculitis. The Kidney in Systemic Autoimmune Diseases 2008, 215-240. Elsevier, Amsterdam. J. Mason, C. Pusey (Eds.).
14. Aucouturier P., Khamlichi A.A., Touchard G., et al. Brief report: heavy chain deposition disease. N Engl J Med 1993, 329:1389-1393.
15. Lin J., Markowitz G.S., Valeri A.M., Kambham N., Sherman W.H., Appel G.B. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001, 12:1482-1492.
16. Nasr S.H., Satoskar A., Markowitz G.S., et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009, 20:2055-2064.
17. Bridoux F., Desport E., Frémeaux-Bacchi V., et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?. Clin J Am Soc Nephrol 2011, 6:2165-2174.
18. Fish R., Pinney J., Jain P., et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010, 5:1977-1980.
19. Iványi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990, 114:986-987.
20. Herrera G.A., Joseph L., Gu X., Hough A., Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004, 128:875-879.
21. Nasr S.H., Valeri A.M., Sethi S., et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies [e-pub ahead of print]. Am J Kidney Dis 2012.
22. Knudsen L.M., Hjorth M., Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000, 65:175-181.
23. Clark W.F., Stewart A.K., Rock G.A., et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005, 14:777-784.
24. Tosi P., Zamagni E., Cellini C., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004, 73:98-103.
25. Kastritis E., Anagnostopoulos A., Roussou M., et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007, 92:546-549.
26. Dimopoulos M., Alegre A., Stadtmauer E.A., et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010, 116:3807-3814.
27. Jagannath S., Barlogie B., Berenson J.R., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005, 103:1195-2000.
28. Chanan-Khan A.A., Kaufman J.L., Mehta J., et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007, 109:2604-2606.
29. Ludwig H., Drach J., Graf H., Lang A., Meran J.G. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematol 2007, 92:1411-1414.
30. San-Miguel J.F., Richardson P.G., Sonneveld P., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
31. Roussou M., Kastritis E., Migkou M., et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008, 49:890-895.
32. Dimopoulos M.A., Richardson P.G., Schlag R., et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009, 27:6086-6093.
33. Dimopoulos M.A., Roussou M., Gavriatopoulou M., et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009, 9:302-306.
34. Morabito F., Gentile M., Ciolli S., et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010, 84:223-228.
35. Ludwig H., Adam Z., Hajek R., et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010, 28:4635-4641.
36. Roussou M., Kastritis E., Christoulas D., Migkou M., Gavriatopoulou M., Grapsa I. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010, 34:1395-1397.
37. Blade J., Fernandez-Llama P., Bosch F., et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998, 158:1889-1893.
38. Tsakiris D.J., Stel V.S., Finne P., et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010, 25:1200-1206.
39. Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
40. Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukemia in adults. Br Med J (Clin Res Ed) 1984, 288:1411-1416.
41. Sanders P.W., Booker B.B. Pathobiology of cast nephropathy from human Bence-Jones proteins. J Clin Invest 1992, 89:630-639.
42. Leung N., Gertz M.A., Zeldenrust S.R., et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008, 73:1282-1288.
43. Burnette B.L., Leung N., Rajkumar S.V. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011, 364:2365-2366.
44. Hutchison C.A., Cockwell P., Reid S., et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007, 18:886-895.
45. Hutchison C.A., Bradwell A.R., Cook M., et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009, 4:745-754.
46. Hutchison C.A., Heyne N., Airia P., et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off hemodialysis [e-pub ahead of print]. Nephrol Dial Transplant 2012.
47. Hutchison C.A., Cockwell P., Stringer S., et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011, 22:1129-1136.
48. Bachmann U., Schindler R., Storr M., Kahl A., Joerres A., Sturm I. Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. Nephrol Dial Transplant 2008, 10.1093/ndtplus/sfm 053.
49. Hutchison C.A., Cook M., Heyne N., et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008, 9:55.
50. Dimopoulos M.A., Terpos E., Chanan-Khan A., et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28:4976-4984.
51. Badros A., Barlogie B., Siegel E., Roberts J., Langmaid C., Zangari M. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822-829.
52. Knudsen L.M., Nielsen B., Gimsing P., Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005, 75:27-33.
53. Lee C.K., Zangari M., Barlogie B., et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004, 33:823-828.
54. Carlson K., Hjorth M., Knudsen L.M. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure-a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005, 128:631-635.
55. Eriksson T., Hoglund P., Turesson I., Waage A., Don B.R., Vu J. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 2003, 55:1701-1706.
56. Fakhouri F., Guerraoui H., Presne C., et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 2004, 125:96-97.
57. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007, 47:1466-1475.
58. Reeder C.B., Reece D.E., Kukreti V., et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009, 23:1337-1341.
59. Khan M.L., Reeder C.B., Kumar S.K., et al. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012, 156:326-333.
60. Ramasamy K., Hazel B., Mahmood S., Corderoy S., Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011, 155:632-634.
61. Pönisch W., Andrea M., Wagner I., et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone [e-pub ahead of print]. J Cancer Res Clin Oncol April 13, 2012.